FULVESTRANT

Faslodex; (7alpha,17beta)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)Sulfinyl]nonyl]estra-1,3,5(10)-triene- 3,17-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; (7R,8R,9S,13S, 14S,17S)- 13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16, 17-decahydrocyclopenta[a] phenanthrene-3,17-diol;

FULVESTRANT
 

PRODUCT IDENTIFICATION

CAS RN

 129453-61-8

EINECS RN

  

FORMULA

 C32H47F5O3S

MOLE WEIGHT

 606.77

CLASSIFICATION

Estrogen Antagonist

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

 white to off-white crystalline powder

MELTING POINT

  

BOILING POINT

  

DENSITY

  

SOLUBILITY IN WATER

Insoluble

pH

  

VAPOR DENSITY

 

REFRACTIVE INDEX

  

FLASH POINT

 

 
STABILITY AND REACTIVITY
STABILITY Stable under normal conditions.

INCOMPATIBLE MATERIALS

Strong oxidizing agents
DECOMPOSITION PRODUCTS

Carbon oxides, Sulphur oxides, Hydrogen fluoride
POLYMERIZATION Has not been reported

NFPA RATINGS

Health:1 , Flammability:0 , Reactivity:1

 

SAFETY

HAZARD NOTES

Target Organ Effect. Target Organs: Reproductive system, Thyroid.

EYE

May cause eye irritation.

SKIN

May be harmful if absorbed through skin. May cause skin irritation.

INGESTION

Harmful if swallowed.

INHALATION

May be harmful if inhaled. May cause respiratory tract irritation.

CHRONIC

  

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

  
HAZARD CLASS

 
PACKING GROUP

 

HAZARD SYMBOL

 

RISK PHRASES

  

SAFETY PHRASES

 

 
EXTERNAL LINKS & GENERAL INFORMATION

Hormone-blocking drugs are preferred to chemotherapy in certain situations. For example, these drugs may be preferred when the cancer is estrogen receptor-positive, when cancer has not recurred for more than 2 years after diagnosis and initial treatment, or when cancer is not immediately life threatening. Different drugs are used in different situations:

  • Tamoxifen: For women who are still menstruating, tamoxifen is usually the first hormone-blocking drug used because it has few side effects.
  • Aromatase inhibitors: For postmenopausal women who have estrogen receptor-positive breast cancer, aromatase inhibitors (such as anastrozole, letrozole, and exemestane) may be more effective as a first treatment than tamoxifen.
  • Progestins: These drugs, such as medroxyprogesterone or megestrol, may be used instead of aromatase inhibitors and tamoxifen and have almost as few side effects.
  •  Fulvestrant: This drug may be used when tamoxifen is no longer effective. It destroys the estrogen receptors in cancer cells. The most common side effect is stomach upset. (http://www.mercksource.com/)
 

 

SALES SPECIFICATION

APPEARANCE

 white to off-white crystalline powder

ASSAY

 98.5 % min (HPLC)

HEAVY METALS

20ppm max

 

PACKING

 

 

PRICE
U$4,000 (5g)